NO972707D0 - Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon - Google Patents

Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Info

Publication number
NO972707D0
NO972707D0 NO972707A NO972707A NO972707D0 NO 972707 D0 NO972707 D0 NO 972707D0 NO 972707 A NO972707 A NO 972707A NO 972707 A NO972707 A NO 972707A NO 972707 D0 NO972707 D0 NO 972707D0
Authority
NO
Norway
Prior art keywords
opioid
modulating
receptor function
receptor
function
Prior art date
Application number
NO972707A
Other languages
English (en)
Other versions
NO972707L (no
Inventor
Olivier Civelli
James Richard Martin
Frederick Monsma
Jean-Luc Moreau
Hans-Peter Nothacker
Rainer Reinscheid
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO972707D0 publication Critical patent/NO972707D0/no
Publication of NO972707L publication Critical patent/NO972707L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO972707A 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon NO972707L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96109462 1996-06-13

Publications (2)

Publication Number Publication Date
NO972707D0 true NO972707D0 (no) 1997-06-12
NO972707L NO972707L (no) 1997-12-15

Family

ID=8222893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972707A NO972707L (no) 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Country Status (17)

Country Link
US (2) US6326156B1 (no)
JP (1) JP3212537B2 (no)
KR (1) KR100247670B1 (no)
CN (1) CN1184254A (no)
AR (1) AR007548A1 (no)
AU (1) AU719519B2 (no)
BR (1) BR9703546A (no)
CA (1) CA2206192A1 (no)
CZ (1) CZ179597A3 (no)
HU (1) HUP9701032A3 (no)
IL (1) IL121017A0 (no)
MX (1) MX9704352A (no)
NO (1) NO972707L (no)
NZ (1) NZ328033A (no)
PL (1) PL320527A1 (no)
TR (1) TR199700482A2 (no)
ZA (1) ZA975077B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
US20080089845A1 (en) * 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2096915A1 (en) * 2006-11-20 2009-09-09 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
EP2598477B1 (en) 2010-07-28 2016-03-02 The Regents of The University of California Peripherally restricted faah inhibitors
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
US6096513A (en) 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
CA2229202C (en) 1995-08-15 2008-05-20 Universite Libre De Bruxells Methods for identifying antagonist or agonist to human opioid receptor-like 1 "orl1"

Also Published As

Publication number Publication date
HUP9701032A3 (en) 2000-04-28
CN1184254A (zh) 1998-06-10
MX9704352A (es) 1997-12-31
BR9703546A (pt) 1998-09-29
US6326156B1 (en) 2001-12-04
KR100247670B1 (ko) 2000-06-01
IL121017A0 (en) 1997-11-20
KR980003586A (ko) 1998-03-30
JP3212537B2 (ja) 2001-09-25
CZ179597A3 (cs) 1998-03-18
NZ328033A (en) 1998-11-25
JPH1068724A (ja) 1998-03-10
US20020082213A1 (en) 2002-06-27
CA2206192A1 (en) 1997-12-13
HUP9701032A2 (hu) 1998-08-28
AU2485397A (en) 1997-12-18
ZA975077B (en) 1997-12-15
PL320527A1 (en) 1997-12-22
AR007548A1 (es) 1999-11-10
HU9701032D0 (en) 1997-07-28
NO972707L (no) 1997-12-15
TR199700482A2 (xx) 1998-01-21
AU719519B2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
NO982732D0 (no) Ny fremgangsmÕte
NO993068D0 (no) Ny forbindelsesform
NO973245D0 (no) Fremgangsmåte ved komplettering av en underjordisk brönn
FI962932A0 (fi) Ankkuriproteiinifunktion modulaattoreita
NO301674B1 (no) Fremgangsmåte for installering av en eller flere instrumentenheter
NO965020L (no) Opprettholdelse av sammensetningen av overförte data ved overlevering
NO972022D0 (no) Fremgangsmåte ved fremstilling av papir
DK0810923T3 (da) Fremgangsmåde til trykning
NO971067D0 (no) Fremgangsmåte for oppgradering av bensin
NO952246L (no) Fremgangsmåte ved installasjon av strekkstagplattform
HUP9701032A3 (en) Modulation of lc132 (opioid-like) receptor function
NO983913D0 (no) Fremgangsmåte for oppfanging av tioler
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
NO301633B1 (no) Fremgangsmåte ved rakettoverföring
DK0874822T3 (da) Ny fremgangsmåde til fremstilling
DE59605202D1 (de) Schnelleinschaltungsverfahren
ID19111A (id) Metoda pembuatan bahan-bahan poliolefin untuk pelapisan
AU1699397A (en) Methods of using integrin modulators
AU4914297A (en) Method of applying dry film photoresist
UA25135A (uk) Спосіб гастроєюhопластики
UA25398A (uk) Спосіб комбіhоваhої холецистолітотомії
UA25653A (uk) Спосіб проведеhhя скальптерапії
NO973547D0 (no) Fremgangsmåte ved fremstilling av papir
GB9619875D0 (en) Method of bridge construction
UA1541S (uk) Комплект етикеток

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application